Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04582539 · OUTCOME

Rate of Red Blood Cell (RBC) Transfusion From Week 12 Through Week 24

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma · Source last updated 2025-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
RBC units per participant-month
Interval / dispersion
Standard Deviation
Time frame
from Week 12 through Week 24

What was measured

The rate of RBC transfusion was defined as the average number of RBC units per participant-month during the treatment period.

Analysis population: Full Analysis Set-MDS. Only participants who were on treatment for at least 78 days were included in the analysis.

Groups in this outcome

Zilurgisertib 50 mg QD

Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.

Zilurgisertib 100 mg QD

Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.

Zilurgisertib 200 mg QD

Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.

Zilurgisertib 400 mg QD

Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.

Zilurgisertib 600 mg QD

Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Zilurgisertib 50 mg QD4
Zilurgisertib 100 mg QD5
Zilurgisertib 200 mg QD4
Zilurgisertib 400 mg QD5
Zilurgisertib 600 mg QD3

Reported measurements

Source class 1
Values in RBC units per participant-month · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Zilurgisertib 50 mg QD2.531.955Not reportedNot reportedNot reported
Zilurgisertib 100 mg QD1.340.948Not reportedNot reportedNot reported
Zilurgisertib 200 mg QD3.012.955Not reportedNot reportedNot reported
Zilurgisertib 400 mg QD2.712.232Not reportedNot reportedNot reported
Zilurgisertib 600 mg QD1.192.067Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.955
        value
        2.53
      2. group Id
        OG001
        spread
        0.948
        value
        1.34
      3. group Id
        OG002
        spread
        2.955
        value
        3.01
      4. group Id
        OG003
        spread
        2.232
        value
        2.71
      5. group Id
        OG004
        spread
        2.067
        value
        1.19
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      5
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      5
    5. group Id
      OG004
      value
      3
    units
    Participants
description
The rate of RBC transfusion was defined as the average number of RBC units per participant-month during the treatment period.
dispersion Type
Standard Deviation
groups
  1. description
    Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.
    id
    OG000
    title
    Zilurgisertib 50 mg QD
  2. description
    Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.
    id
    OG001
    title
    Zilurgisertib 100 mg QD
  3. description
    Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.
    id
    OG002
    title
    Zilurgisertib 200 mg QD
  4. description
    Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.
    id
    OG003
    title
    Zilurgisertib 400 mg QD
  5. description
    Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.
    id
    OG004
    title
    Zilurgisertib 600 mg QD
param Type
MEAN
population Description
Full Analysis Set-MDS. Only participants who were on treatment for at least 78 days were included in the analysis.
reporting Status
POSTED
time Frame
from Week 12 through Week 24
title
Rate of Red Blood Cell (RBC) Transfusion From Week 12 Through Week 24
type
SECONDARY
unit Of Measure
RBC units per participant-month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice